HRP20110524T1 - Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju - Google Patents

Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju Download PDF

Info

Publication number
HRP20110524T1
HRP20110524T1 HR20110524T HRP20110524T HRP20110524T1 HR P20110524 T1 HRP20110524 T1 HR P20110524T1 HR 20110524 T HR20110524 T HR 20110524T HR P20110524 T HRP20110524 T HR P20110524T HR P20110524 T1 HRP20110524 T1 HR P20110524T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
disease
hydrate
patient
Prior art date
Application number
HR20110524T
Other languages
English (en)
Croatian (hr)
Inventor
A. Gray Julian
Yoshiharu Yamanishi
Nobuyuki Mori
Fields Scott
Original Assignee
Eisai R&D Management Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co. filed Critical Eisai R&D Management Co.
Publication of HRP20110524T1 publication Critical patent/HRP20110524T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20110524T 2005-04-04 2011-07-12 Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju HRP20110524T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66766505P 2005-04-04 2005-04-04
US68951905P 2005-06-13 2005-06-13
PCT/US2006/012284 WO2006107859A2 (en) 2005-04-04 2006-04-04 Dihydropyridine compounds for neurodegenerative diseases and dementia

Publications (1)

Publication Number Publication Date
HRP20110524T1 true HRP20110524T1 (hr) 2011-08-31

Family

ID=37074003

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110524T HRP20110524T1 (hr) 2005-04-04 2011-07-12 Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju

Country Status (16)

Country Link
US (3) US20090131480A1 (ja)
EP (2) EP1871369A4 (ja)
JP (2) JP5180816B2 (ja)
KR (1) KR20080007233A (ja)
AT (1) ATE511843T1 (ja)
AU (1) AU2006232517A1 (ja)
CA (1) CA2603258A1 (ja)
CY (1) CY1112427T1 (ja)
DK (1) DK1871368T3 (ja)
HR (1) HRP20110524T1 (ja)
IL (1) IL186412A0 (ja)
ME (1) ME01224B (ja)
PL (1) PL1871368T3 (ja)
PT (1) PT1871368E (ja)
RS (1) RS51822B (ja)
WO (2) WO2006107860A2 (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4614884B2 (ja) * 2003-11-14 2011-01-19 シャンハイ ゲノミックス インク ピリドンの誘導体とその使用
CA2603258A1 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
US20090030017A1 (en) * 2005-04-08 2009-01-29 Eisai R & D Management Co., Ltd Therapeutic agent for dyskinesia
PL1928454T3 (pl) 2005-05-10 2015-03-31 Intermune Inc Pochodne pirydonu do modulowania układu kinazy białkowej aktywowanego stresem
WO2007126060A1 (ja) * 2006-04-28 2007-11-08 Eisai R & D Management Co., Ltd 1,2-ジヒドロピリジン化合物の塩
MX2009004516A (es) * 2006-10-27 2009-08-12 Medivation Neurology Inc Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
AU2008210455A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
US20100168174A1 (en) * 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
WO2009054543A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
US20100297181A1 (en) * 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 三環式ピラゾロピリジンキナーゼ阻害剤
CN102131807B (zh) 2008-07-23 2013-11-20 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
AU2009279611A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
WO2010072605A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
MX2011006843A (es) 2008-12-23 2011-08-04 Hoffmann La Roche Dihidropiridona-amidas como moduladores de p2x7.
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
JP2012513435A (ja) 2008-12-23 2012-06-14 エフ.ホフマン−ラ ロシュ アーゲー P2x7調節薬としてのジヒドロピリドンアミド
EP2385939A1 (en) 2008-12-23 2011-11-16 F. Hoffmann-La Roche AG Dihydropyridone amides as p2x7 modulators
CA2760705A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
MX2012008644A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasa de pirazolopiridinas.
AU2011209651A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
AU2011209649A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
DK2849781T3 (en) 2012-03-12 2017-10-16 William J Binder TREATMENT OF MIGRINE HEAD PAIN WITH PRESYNAPTIC NEUROTOXIN
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
TW201441193A (zh) 2012-12-06 2014-11-01 Kyowa Hakko Kirin Co Ltd 吡啶酮化合物
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
US10703746B2 (en) 2014-12-22 2020-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
RU2742173C2 (ru) * 2016-04-26 2021-02-02 Х. Лундбекк А/C Применение ингибитора ацетилхолинэстеразы и идалопирдина для снижения риска падений у пациентов с болезнью паркинсона
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2023042887A1 (ja) * 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物
WO2023042888A1 (ja) * 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
JP3075566B2 (ja) 1990-05-15 2000-08-14 エーザイ株式会社 光学活性インダノン誘導体
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 (―)―1―ベンジル―4―〔(5,6―ジメトキシ―1―インダノン)―2―イル〕メチルピペリジンの製造方法
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5843945A (en) 1993-05-13 1998-12-01 Neurosearch A/S AMPA antagonists and a method of treatment
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
PL181532B1 (pl) * 1994-09-27 2001-08-31 Yamanouchi Pharma Co Ltd Pochodne 1,2,3,4-tetrahydrochinoksalinodionu PL PL PL PL PL PL PL PL PL
HU228434B1 (en) 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1998017672A1 (de) * 1996-10-24 1998-04-30 Novartis Ag Substituierte aminoalkanphosphonsäuren
JP4095676B2 (ja) * 1997-03-03 2008-06-04 エーザイ株式会社 注意障害を治療するためのコリンエステラーゼ阻害剤の使用
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE69822218T2 (de) * 1997-12-05 2005-02-03 Eisai Co., Ltd. Donepezil polykristalle und verfharen zu ihrer herstellung
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス,インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
IT1304904B1 (it) * 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
FR2805260A1 (fr) * 2000-02-18 2001-08-24 Adir Nouveaux derives d'acides 6-sulfamoyl-3-quinolinyl phosphoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003525903A (ja) * 2000-03-03 2003-09-02 エーザイ株式会社 コリンエステラーゼ阻害剤の新規使用法
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030144255A1 (en) * 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
ATE420862T1 (de) * 2000-06-12 2009-01-15 Eisai R&D Man Co Ltd 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
JP2002047272A (ja) * 2000-07-26 2002-02-12 Dai Ichi Seiyaku Co Ltd ポリアミンアミド誘導体
HU228961B1 (en) * 2000-09-18 2013-07-29 Eisai R & D Man Co Triazinones and their use as active ingredients of pharmaceutical compositions
WO2003024456A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
JP4208512B2 (ja) * 2002-07-23 2009-01-14 株式会社クラレ 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
MY148809A (en) * 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
CA2603258A1 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches

Also Published As

Publication number Publication date
JP2008537552A (ja) 2008-09-18
US20090131480A1 (en) 2009-05-21
WO2006107859A2 (en) 2006-10-12
EP1871368A4 (en) 2009-11-11
EP1871368B1 (en) 2011-06-08
PL1871368T3 (pl) 2011-12-30
EP1871369A2 (en) 2008-01-02
WO2006107860A3 (en) 2009-04-09
US20060270709A1 (en) 2006-11-30
JP2008538216A (ja) 2008-10-16
EP1871369A4 (en) 2009-11-11
RS51822B (en) 2012-02-29
US20060276510A1 (en) 2006-12-07
CY1112427T1 (el) 2015-12-09
DK1871368T3 (da) 2011-09-19
IL186412A0 (en) 2008-08-07
EP1871368A2 (en) 2008-01-02
WO2006107859A3 (en) 2009-04-09
AU2006232517A1 (en) 2006-10-12
WO2006107859A8 (en) 2007-11-08
PT1871368E (pt) 2011-08-30
ME01224B (me) 2013-06-20
CA2603258A1 (en) 2006-10-12
KR20080007233A (ko) 2008-01-17
WO2006107860A2 (en) 2006-10-12
JP5180816B2 (ja) 2013-04-10
ATE511843T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
HRP20110524T1 (hr) Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
ATE502017T1 (de) Pyrazolderivate als p2x7-modulatoren
JP2012508734A5 (ja)
WO2008111590A3 (en) Ampa and nmda receptor antagonists for neurodegenerative diseases
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
WO2007003330A3 (de) Pharmazeutische darreichungsformen enthaltend eine wirkstoffkombination von nifedipin und/oder nisoldipin und einem angiotensin-ii antagonisten
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
HRP20200872T1 (hr) Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze
JP2017531692A5 (ja)
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
JP2013518914A5 (ja)
WO2007092861A3 (en) Inhibitors specific of presenilin-1 and their uses
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
MX2021007780A (es) Composiciones y metodos para tratar trastornos neurodegenerativos.
JP2016514688A5 (ja)
TW200732304A (en) Piperidine derivatives
HRP20201412T1 (hr) Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda
EA036542B9 (ru) Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
NZ611529A (en) Glucagon receptor modulators
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
JP2013536206A5 (ja)
KR100599350B1 (ko) 알츠하이머 치매와 같은 노인성 치매 치료용의 활성 성분들, 특히, 테트라히드로피리딘류 및 아세틸콜린에스테라아제 억제제의 배합물
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
RU2013147196A (ru) Агонист рецептора 5-нт4 в качестве прокинетического агента